Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

NCT03212807 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds

Conditions

EBV Related Non-Hodgkin's Lymphoma
Primary CNS Lymphoma
Primary Testicular Lymphoma

Interventions

DRUG: Durvalumab
DRUG: Lenalidomide

Sponsor

Singapore General Hospital

Collaborators

[object Object]
[object Object]
[object Object]